Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

How much does MOTS-c cost?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Not covered by commercial plans or Medicare because it is an unapproved compounded product.

Regulatory: HHS interim policy (draft)Verified: Verified Oct 28, 2026
With insurance
Not published
Compounded pharmacy
Not published

What each price includes, with sources

What does MOTS-c cost in each channel?

Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.

MOTS-c price by purchase channel
ChannelPrice (USD)Notes
With insuranceNot publishedNot covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [4]
Compounded pharmacyNot publishedNo verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient MOTS-c under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for subcutaneous or intramuscular injection, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7]

What is the list price of MOTS-c?

There is no list price: MOTS-c is not an FDA approved drug. Research chemical products sold for human use are unapproved drugs, and their listings are not a comparable price.

Does insurance cover MOTS-c?

Not covered by commercial plans or Medicare because it is an unapproved compounded product.

What changes the price?

  • HHS's October 2026 draft policy covers only single-ingredient compounding under conditions (patient-specific prescription, allowed route, tested substance from an FDA-registered manufacturer); blends are excluded and no qualifying pharmacy price has been verified yet

Frequently asked questions

How much does MOTS-c cost without insurance?

No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient MOTS-c under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for subcutaneous or intramuscular injection, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7]

Does insurance cover MOTS-c?

Not covered by commercial plans or Medicare because it is an unapproved compounded product. [4]

What is the list price of MOTS-c?

There is no list price: MOTS-c is not an FDA approved drug. Research chemical products sold for human use are unapproved drugs, and their listings are not a comparable price.

From the blog

Sources

  1. [1]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA
  2. [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
  3. [3]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
  4. [4]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
  5. [5]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  6. [6]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, HHS notice of availability of a draft policy, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496 (public inspection copy; publication scheduled October 30, 2026)Federal Register, 2026
  7. [7]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026